semaj83/ctmatch_classification huggingface dataset:
Patient description: A 4 year old boy presents to the emergency room with wheezing. He has had a history of allergic rhinitis, but no history of wheezing. His mother reports that 5 hours ago patient was playing in the backyard sandbox when she heard him suddenly start coughing. The coughing lasted only moments, but he has been audibly wheezing since. Mother was concerned, because his breathing has not returned to normal, so she brought him to the ED. On exam, the child is playful and well appearing. Wheezing is heard in the mid-right chest area. O2 sats are 100% on room air.

Clinical trial eligibility criteria: eligible ages (years): 14.0-17.0,  Allergic Rhinitis Asthma Clinical cases n°: 600 adolescents affected by allergic rhinitis with/without asthma, from 14 to 17 years age Controls n°: 600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology  Subjects that have not allergic rhinitis with/without asthma diagnosis or are <14 years old or >17 years old
Patient description: A 4 year old boy presents to the emergency room with wheezing. He has had a history of allergic rhinitis, but no history of wheezing. His mother reports that 5 hours ago patient was playing in the backyard sandbox when she heard him suddenly start coughing. The coughing lasted only moments, but he has been audibly wheezing since. Mother was concerned, because his breathing has not returned to normal, so she brought him to the ED. On exam, the child is playful and well appearing. Wheezing is heard in the mid-right chest area. O2 sats are 100% on room air.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Allergic Rhinitis persistent allergic rhinitis  the presence of asthma or nasal polyps acute and chronic upper respiratory infections administration of intranasal or systemic corticosteroids or H1 antihistamines in the past 30 days
Patient description: A 4 year old boy presents to the emergency room with wheezing. He has had a history of allergic rhinitis, but no history of wheezing. His mother reports that 5 hours ago patient was playing in the backyard sandbox when she heard him suddenly start coughing. The coughing lasted only moments, but he has been audibly wheezing since. Mother was concerned, because his breathing has not returned to normal, so she brought him to the ED. On exam, the child is playful and well appearing. Wheezing is heard in the mid-right chest area. O2 sats are 100% on room air.

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Chronic Obstructive Pulmonary Disease Provide informed consent Males not donating sperm and using adequate contraception or females who are surgically sterile or postmenopausal lead ECG showing:Heart rate 45 to 90 bpm, QTcF≤450 msec, QRS ≤120 msec, PR interval ≤220 msec, no clinically significant abnormality Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly BMI 18 to 33 kg/m2 with a minimum weight of 45 kg COPD diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two puffs of ipratropium) via spirometry Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of ≤0.70 Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal ≥150 mL increase from pre-bronchodilator FEV1  History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation COPD exacerbation requiring oral steroids in the previous 3 months History of one or more hospitalisations for COPD in the previous 12 months Respiratory tract infection (both upper and lower) treated with antibiotics in previous 12 weeks Evidence of cor pulmonale or clinically significant pulmonary hypertension Other respiratory disorders Previous lung resection or lung reduction surgery Oral therapies for COPD in the previous 3 months and throughout the study Drug or alcohol abuse in the past 3 years Received an experimental drug within 3 months or five half lives, whichever is longer
Patient description: A 4 year old boy presents to the emergency room with wheezing. He has had a history of allergic rhinitis, but no history of wheezing. His mother reports that 5 hours ago patient was playing in the backyard sandbox when she heard him suddenly start coughing. The coughing lasted only moments, but he has been audibly wheezing since. Mother was concerned, because his breathing has not returned to normal, so she brought him to the ED. On exam, the child is playful and well appearing. Wheezing is heard in the mid-right chest area. O2 sats are 100% on room air.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Allergic Rhinitis Adults and children from the age of 12 years on, who are diagnosed with recurrent seasonal allergic rhinitis (SAR) caused by grass pollen A previous specific immunotherapy finished at least five years ago had to be successful  Contraindications according to the patient information leaflet
Patient description: A 4 year old boy presents to the emergency room with wheezing. He has had a history of allergic rhinitis, but no history of wheezing. His mother reports that 5 hours ago patient was playing in the backyard sandbox when she heard him suddenly start coughing. The coughing lasted only moments, but he has been audibly wheezing since. Mother was concerned, because his breathing has not returned to normal, so she brought him to the ED. On exam, the child is playful and well appearing. Wheezing is heard in the mid-right chest area. O2 sats are 100% on room air.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C ≥18 years of age 2 consecutive positive HCV RNA tests at least 6 months after estimated date of infection HCV genotype 1 HCV RNA <6 million copies by Roche TaqMan Assay No evidence of hepatic cirrhosis (as determined by two indices: Fib4<3.25—an accurate test for detecting cirrhosis based on age, AST, ALT and platelets [sensitivity/specificity 76-100/82-91%], confirmed by the fibrosis-cirrhosis index (FCI)<1.25 based on ALT, bilirubin, albumin and platelets [sensitivity/specificity 86/100%]) Drug injection in past 30 days by self-report and physical exam evidence of injection drug use (e.g. track marks) injected with others in past 12 months by self-report Lab values within acceptable range (platelets>50,000, creatinine clearance by Cockroft-Gault>30mL/min, hemoglobin >10g/dL, INR<1.5 x upper limit of normal (ULN) unless stable on anticoagulant regimen or known hemophilia, AST/ALT<10 x ULN) Able to speak English No plans to leave San Francisco area for at least 9 months and either lives or works in San Francisco, or travels to San Francisco at least weekly  HIV+ by rapid test or pooled viral load HBV surface antigen + Non-definitive HCV genotype results Previously received treatment for HCV (interferon, ribavirin, or DAA) Taking medications that affect pharmacokinetics of LDV-SOF (proton-pump inhibitors, anticonvulsants [phenobarbital, phenytoin, carbamazepine, oxcarbazepine], rifamycins, rosuvastatin, herbs [St. John's wort, silymarin, echinacea]) History of any of the following Current gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug History of hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage) History of solid organ or bone marrow transplantation Current treatment for cancer
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 16.0-23.0,  Cervical Cancer Genital Warts Female with an intact uterus with lifetime history of 0-4 sexual partners  Prior Human Papillomavirus (HPV) vaccination Prior abnormal paps History of genital warts
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cervix Neoplasms Women with ONLY the following results on a routine Pap smear Low grade epithelial abnormality Minor changes in squamous cell Minor changes in squamous cells with appearances consistent with Papillomavirus Women aged between 18-70 years  Women who are pregnant or planning to become pregnant in the next 12 months Women with previous Pap smear abnormality for 2 years
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 20.0-30.0,  Papillomavirus Infection Participated in study 580299/001 and received all three doses of vaccine/placebo Written informed consent obtained from the subject prior to enrollment  Decoding of the subject's treatment allocation to either the subject or the investigator in study 580299/001
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 15.0-25.0,  Infections, Papillomavirus A woman whom the investigator believes that she and/or her parents/legally acceptable representative can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) A woman between, and including, 15 and 25 years of age at the time of the first vaccination Written informed consent must be obtained from the subject prior to enrollment (for subjects below the legal age of consent, written informed consent must be obtained from a parent or legal guardian of the subject and, in addition, the subject should sign and personally date a written informed assent) Subject must be free of obvious health problems as established by medical history and clinical examination before entering into the study Subject must have a negative urine pregnancy test Subject must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or must be using adequate contraceptive precautions for 30 days prior to the first vaccination and must agree to continue such precautions for two months after completion of the vaccination series Has had no more than 6 lifetime sexual partners prior to enrollment. This criterion may not be applicable in subjects less than 18 years of age, according to local regulatory/ethical requirements Subject must have intact cervix  Pregnant or breastfeeding. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study A woman planning to become pregnant or planning to discontinue contraceptive precautions during approximately the first nine months of the study (Months 0-8) Previous administration of components of the investigational vaccine Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. days 0-29) each dose of vaccine. Administration of some routine vaccines up to 8 days before each dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window Previous vaccination against human papillomavirus (HPV) History of vaccination against Hepatitis A or a known clinical history of Hepatitis A disease History of having had colposcopy or has planned a colposcopy to evaluate an abnormal cervical cytology (Pap smear) test Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 26.0-999.0,  Infections, Papillomavirus A woman who the investigator believes that she can and will comply with the requirements of the protocol A women of at least 26 years of age at the time of the first vaccination Written informed consent obtained from the subject prior to enrolment Free of obvious health problems as established by medical history and clinical examination before entering into the study Subject must have intact cervix Subject must have a negative urine pregnancy test. This test is not applicable to women of non-childbearing potential Subject must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or must be using an effective method of birth control for 30 days prior to the first vaccination and must agree to continue such precautions for two months after completion of the vaccination series  Pregnant or breastfeeding (women must be at least three months post-pregnancy and not breastfeeding to enter the study) A women planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose (Month 0 Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 84) Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. days 0 the first dose of study vaccine. Planned administration/administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window Previous administration of components of the investigational vaccine Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period History of HPV infection/treatment or planned treatment to evaluate an abnormal cervical cytology (Pap smear) test, e.g. colposcopy Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 20.0-25.0,  Human Papillomavirus (HPV) Infection Papillomavirus Vaccines Cervical Neoplasia Subjects who the investigator/co-investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study A Japanese female subject between, and including, 20 and 25 years of age at the time of the first vaccination Written informed consent obtained from the subject prior to enrolment Healthy subjects as established by medical history and history-oriented clinical examination before entering into the study Subjects must have a negative urine pregnancy test Subjects must be of non-childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series Subject must have an intact cervix  Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine/control within 30 days preceding the first dose of study vaccine/control, or planned use during the study period Pregnant or breastfeeding women. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period, up to 2 months after the last vaccine dose previous administration of components of the investigational vaccine Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine. Routine vaccines may be allowed up to 8 days before the first dose of study vaccine Previous vaccination against HPV History of vaccination against hepatitis A or a known clinical history of hepatitis A disease Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Papillomavirus Infections HIV Infections HIV-infected men who have sex with men
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 21.0-100.0,  Cervical Neoplasia Women in KPNC aged 25 years or older who tested positive for HPV Will also a random sample of women who tested negative for HPV  Male Children under 18
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 26.0-65.0,  Cervical Intraepithelial Neoplasia Five-hundred women attending colposcopy and 500 women receiving cytology screening, including 250 unscreened women, will be recruited for the study. Non-pregnant, non-hysterectomized women aged 26-65 will be recruited  Women under 26 or over 65 years of age Pregnant women or women having given birth to a child in the past 8 weeks. To insure women included in the study are not pregnant, we will ask women during the consenting process if they are pregnant. Women who answer yes for either query will be excluded. Participants will also receive a reminder call for their 2-week self-collection. At that time, women again will be asked if they are pregnant. If any woman answers yes, she will be instructed to not self-collect Women who have had a total hysterectomy Women who have an overt cancerous lesion visible upon exam by the clinician Other reasons to women the inability to speak English, the appearance of mental incompetence, or refusal to participate or sign the informed consent form
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Precancerous Condition Underwent Pap smear, human papillomavirus (HPV) testing, and HIV testing AND meets any of the following Biopsy and colposcopy confirmed cervical intraepithelial neoplasia (CIN) or invasive cervical cancer (ICC), meeting any of the following CIN grade 2-3 or higher Repeated CIN1 (times 6) Abnormal Pap smear (atypical squamous cells of undetermined significance [ASCUS] or worse) HIV seropositive Negative cytology but positive for high-risk human papillomavirus (HPV) Negative cytology and negative HPV HIV negative (without biopsy-proven CIN 3 or worse) and high-risk HPV infection (types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 55, 56, 58, 59, 68, 82, 83, 73) >= 18 years of age  < 18 years of age Pregnant at screening Cervix not intact not able to provide informed consent
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Cervical Cancer Screening Women from 25 to 65 years of age, registered with the Medical Services Plain in BC attending a collaborating healthcare provider for routine cervical screening in Metro Vancouver or Greater Victoria  pregnant history of invasive cervical cancer no cervix HIV positive or on immunosuppressive treatments unable or unwilling to give informed consent Treatment of moderate or greater dysplasia within last 5 years
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 18.0-26.0,  Papillomavirus Infections Women between 18 and 26 years of age Women able to consent for themselves Referring Pap smear was ASCUS, + HPV or LGSIL Women who decide they wish to get the Gardasil vaccination series  Women who have had previous cryotherapy of the cervix, LEEP or cervical conization Women who had their first Gardasil injection prior to their referring Pap smear Women under the age of 18 Women unable to consent for themselves Women who are pregnant currently trying to conceive Women in an immunocompromised state (diabetes, HIV, on chronic immunosuppressants or steroids, etc) Women who do not want the Gardasil vaccination series
Patient description: A 32 year old female with no previous medical history presents to clinic to discuss lab results from her most recent pap smear. She reports no complaints and is in general good health. The results of her PAP were cytology negative, HPV positive.

Clinical trial eligibility criteria: eligible ages (years): 15.0-25.0,  Infections, Papillomavirus Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study Subjects who participated in study 580299-007 Written informed consent obtained from the subject prior to enrollment  Use or planned use of any investigational or non-registered product other than the study vaccine Decoding of the subject's 580299-001 treatment allocation to either the subject or the investigator Administration or planned administration of any other HPV vaccine, other than the vaccine administered in study 580299-001